Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Microbot Medical ( (MBOT) ) has issued an update.
Microbot Medical Inc. announced the completion of significant milestones in 2024, including the FDA 510(k) submission for its LIBERTY Endovascular Robotic Surgical System, as it prepares for its commercial launch in 2025. The achievements, such as successful clinical trials and strategic partnerships, lay a strong foundation for future growth and market expansion, with the company anticipating the U.S. launch in Q2 2025 and seeking further regulatory approvals internationally.
More about Microbot Medical
Microbot Medical Inc. is a pre-commercial stage medical technology company focused on improving the quality of care for patients and providers globally. The company has developed the world’s first single-use, fully disposable endovascular robotic system, aimed at overcoming traditional barriers to accessing advanced robotic systems.
YTD Price Performance: -32.32%
Average Trading Volume: 231,246
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $18.79M
Learn more about MBOT stock on TipRanks’ Stock Analysis page.
Trending Articles
- Netflix (NASDAQ:NFLX) Lands Huge Win With “Squid Game 2”
- Ford (NYSE:F) Lands New Patent for “Steer-by-Wire” System
- Intel (NASDAQ:INTC) Looking Into Battlemage Followup
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
